Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: Time for a re-evaluation?

Current Opinion in Cardiology

Volumn 21, Issue 4, 2006, Pages 376-384

  Lekas, Michael ^a   Lekas, Poli ^d   Latter, David A ^a   Kutryk, Michael B ^a,b   Stewart, Duncan J ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Angiogenesis; Gene therapy; Ischaemic vascular disease; Neovascularization; Therapeutic

Indexed keywords

ADENOVIRUS VECTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; PLACEBO; RECOMBINANT FIBROBLAST GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN 165; VASCULOTROPIN A;

ANGIOGENESIS; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EXERCISE TOLERANCE; GENE THERAPY; GENE TRANSFER; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART TAMPONADE; HINDLIMB; HUMAN; INTERMITTENT CLAUDICATION; NONHUMAN; PATIENT SELECTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; SEPSIS; SHEAR STRESS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ST SEGMENT; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VASCULAR DISEASE; VIRAL GENE DELIVERY SYSTEM; VISUAL IMPAIRMENT;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ARTERIAL OCCLUSIVE DISEASES; ARTERIES; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; FIBROBLAST GROWTH FACTORS; GENE THERAPY; HUMANS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RESEARCH DESIGN; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 33748191608     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000231409.69307.d2     Document Type: Review

References (65)

1. Gill M, Dias S, Hattori K, et al. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ Res 2001; 88:167-174.
2. Dormandy J, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg 1999; 12:142-147.
3. Dormandy J, Heeck L, Vig S. Major amputations: clinical patterns and predictors. Semin Vasc Surg 1999; 12:154-161.
4. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97:1114-1123.
5. Feinglass J, Brown JL, LoSasso A, et al. Rates of lower-extremity amputation and arterial reconstruction in the United States 1979 to 1996. Am J Public Health 1999; 89:1222-1227.
6. Conway EM, Collen D, Carmeliet P. Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001; 49:507-521.
7. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275:964-967.
8. Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999; 5:434-438.
9. Scholz D, Ito W, Fleming I, et al. Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis). Virchows Arch 2000; 436:257-270.
10. Peichev M, Naiyer AJ, Pereira D, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95:952-958.
11. Kalka C, Masuda H, Takahashi T, et al. Vascular endothelial growth factor(165) gene transfer augments circulating endothelial progenitor cells in human subjects. Circ Res 2000; 86:1198-1202.
12. Kalka C, Tehrani H, Laudenberg B, et al. VEGF gene transfer mobilizes endothelial progenitor cells in patients with inoperable coronary disease. Ann Thorac Surg 2000; 70:829-834.
13. Iwaguro H, Yamaguchi J, Kalka C, et al. Endothelial progenitor cell vascular endothelial growth factor gene transfer for vascular regeneration. Circulation 2002; 105:732-738.
14. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6:460-463.
15. Suri C, Jones PF, Patan S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87:1171-1180.
16. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380:435-439.
17. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, et al. Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res 2001; 49:659-670.
18. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002; 3:411-423.
19. Carmeliet P. Fibroblast growth factor-1 stimulates branching and survival of myocardial arteries: a goal for therapeutic angiogenesis? Circ Res 2000; 87:176-178.
20. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003; 9:604-613.
21. Cooke JP, Losordo DW. Nitric oxide and angiogenesis. Circulation 2002; 105:2133-2135.
22. Ziche M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994; 94:2036-2044.
23. Murohara T, Witzenbichler B, Spyridopoulos I, et al. Role of endothelial nitric oxide synthase in endothelial cell migration. Arterioscler Thromb Vasc Biol 1999; 19:1156-1161.
24. Babaei S, Teichert-Kuliszewska K, Monge JC, et al. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 1998; 82:1007-1015.
25. Babaei S, Teichert-Kuliszewska K, Zhang Q, et al. Angiogenic actions of angiopoietin-1 require endothelium-derived nitric oxide. Am J Pathol 2003; 162:1927-1936.
26. Heil M, Schaper W. Pathophysiology of collateral development. Coron Artery Dis 2004; 15:373-378.
27. Heil M, Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res 2004; 95:449-458.
28. Kersten JR, Pagel PS, Chilian WM, Warltier DC. Multifactorial basis for coronary collateralization: a complex adaptive response to ischemia. Cardiovasc Res 1999; 43:44-57.
29. Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol 2003; 23:1143-1151.
30. Heilmann C, Beyersdorf F, Lutter G. Collateral growth: cells arrive at the construction site. Cardiovasc Surg 2002; 10:570-578.
31. Hoefer IE, van Royen N, Rectenwald JE, et al. Arteriogenesis proceeds via ICAM-1/Mac-1-mediated mechanisms. Circ Res 2004; 94:1179-1185.
32. Arras M, Ito WD, Scholz D, et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest 1998; 101:40-50.
33. Ito WD, Arras M, Winkler B, et al. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. Circ Res 1997; 80:829-837.
34. Heil M, Ziegelhoeffer T, Wagner S, et al. Collateral artery growth (arteriogenesis) after experimental arterial occlusion is impaired in mice lacking CC-chemokine receptor-2. Circ Res 2004; 94:671-677.
35. van Royen N, Hoefer I, Buschmann I, et al. Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J 2002; 16:432-434.
36. Scholz D, Ziegelhoeffer T, Helisch A, et al. Contribution of arteriogenesis and angiogenesis to postocclusive hindlimb perfusion in mice. J Mol Cell Cardiol 2002; 34:775-787.
37. Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359:2053-2058.
38. Rajagopalan S, Mohler ER III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108:1933-1938.
39. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003; 107:1359-1365.
40. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002; 105:788-793.
41. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105:1291-1297.
42. Doukas J, Blease K, Craig D, et al. Delivery of FGF genes to wound repair cells enhances arteriogenesis and myogenesis in skeletal muscle. Mol Ther 2002; 5:517-527.
43. Stewart DJ, Hilton JD, Arnold MO et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: A phase 2 randomized controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment. Gene therapy 2006; in press.
44. Kornowski R, Fuchs S, Epstein SE, et al. Catheter-based plasmid-mediated transfer of genes into ischemic myocardium using the pCOR plasmid. Coron Artery Dis 2000; 11:615-619.
45. Kornowski R, Fuchs S, Leon MB, Epstein SE. Delivery strategies to achieve therapeutic myocardial angiogenesis. Circulation 2000; 101:454-458.
46. Kastrup J, Jorgensen E, Ruck A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol 2005; 45:982-988. The EUROINJECT-I phase II randomized double-blind trial, in which therapeutic angiogenesis of percutaneous intramyocardial plasmid gene transfer of phVEGF-A165 on myocardial perfusion, left ventricular function, and clinical symptoms was assessed.
47. Lazarous DF, Shou M, Stiber JA, et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc Res 1997; 36:78-85.
48. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100:468-474.
49. Schumacher B, Pecher P, von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998; 97:645-650.
50. Assmus B, Schachinger V, Teupe C, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCAREAMI). Circulation 2002; 106:3009-3017.
51. Ito WD, Arras M, Scholz D, et al. Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion. Am J Physiol 1997; 273:H1255-H1265.
52. Deindl E, Buschmann I, Hoefer IE, et al. Role of ischemia and of hypoxiainducible genes in arteriogenesis after femoral artery occlusion in the rabbit. Circ Res 2001; 89:779-786.
53. Seiler C, Pohl T, Wustmann K, et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001; 104:2012-2017.
54. Cao R, Brakenhielm E, Pawliuk R, et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003; 9:604-613.
55. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42:1149-1160.
56. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23:168-175.
57. Sobrevia L, Mann GE. Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia. Exp Physiol 1997; 82:423-452.
58. Zhao X, Lu X, Feng Q. Deficiency in endothelial nitric oxide synthase impairs myocardial angiogenesis. Am J Physiol Heart Circ Physiol 2002; 283:H2371-H2378.
59. Rivard A, Silver M, Chen D, et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154:355-363.
60. Tamarat R, Silvestre JS, Huijberts M, et al. Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proc Natl Acad Sci U S A 2003; 100:8555-8560.
61. Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159:513-525.
62. Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: a potential predictor for the individual capacity to develop collaterals. Circulation 2000; 102:185-190.
63. Duan J, Murohara T, Ikeda H, et al. Hypercholesterolemia inhibits angiogenesis in response to hindlimb ischemia: nitric oxide-dependent mechanism. Circulation 2000; 102 (19 Suppl. 3):III370-III376.
64. Sasaki K, Duan J, Murohara T, et al. Rescue of hypercholesterolemia- related impairment of angiogenesis by oral folate supplementation. J Am Coll Cardiol 2003; 42:364-372.
65. Duan J, Murohara T, Ikeda H, et al. Hyperhomocysteinemia impairs angiogenesis in response to hindlimb ischemia. Arterioscler Thromb Vasc Biol 2000; 20:2579-2585.